Literature DB >> 33712513

Harnessing the Benefits of Neuroinflammation: Generation of Macrophages/Microglia with Prominent Remyelinating Properties.

Manoj Kumar Mishra1, Khalil S Rawji1, Michael B Keough1, Janson Kappen1, Reza Dowlatabadi2, Hans J Vogel2, Sameeksha Chopra3,4, Félix Distéfano-Gagné5, Antoine Dufour3,4, David Gosselin5, V Wee Yong6.   

Abstract

Excessive inflammation within the CNS is injurious, but an immune response is also required for regeneration. Macrophages and microglia adopt different properties depending on their microenvironment, and exposure to IL4 and IL13 has been used to elicit repair. Unexpectedly, while LPS-exposed macrophages and microglia killed neural cells in culture, the addition of LPS to IL4/IL13-treated macrophages and microglia profoundly elevated IL10, repair metabolites, heparin binding epidermal growth factor trophic factor, antioxidants, and matrix-remodeling proteases. In C57BL/6 female mice, the generation of M(LPS/IL4/IL13) macrophages required TLR4 and MyD88 signaling, downstream activation of phosphatidylinositol-3 kinase/mTOR and MAP kinases, and convergence on phospho-CREB, STAT6, and NFE2. Following mouse spinal cord demyelination, local LPS/IL4/IL13 deposition markedly increased lesional phagocytic macrophages/microglia, lactate and heparin binding epidermal growth factor, matrix remodeling, oligodendrogenesis, and remyelination. Our data show that a prominent reparative state of macrophages/microglia is generated by the unexpected integration of pro- and anti-inflammatory activation cues. The results have translational potential, as the LPS/IL4/IL13 mixture could be locally applied to a focal CNS injury to enhance neural regeneration and recovery.SIGNIFICANCE STATEMENT The combination of LPS and regulatory IL4 and IL13 signaling in macrophages and microglia produces a previously unknown and particularly reparative phenotype devoid of pro-inflammatory neurotoxic features. The local administration of LPS/IL4/IL13 into spinal cord lesion elicits profound oligodendrogenesis and remyelination. The careful use of LPS and IL4/IL13 mixture could harness the known benefits of neuroinflammation to enable repair in neurologic insults.
Copyright © 2021 the authors.

Entities:  

Keywords:  macrophages; microglia; neuroinflammation; oligodendrocyte; remyelination

Year:  2021        PMID: 33712513      PMCID: PMC8051677          DOI: 10.1523/JNEUROSCI.1948-20.2021

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  85 in total

1.  Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord.

Authors:  Kristina A Kigerl; John C Gensel; Daniel P Ankeny; Jessica K Alexander; Dustin J Donnelly; Phillip G Popovich
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

2.  Systemic injections of lipopolysaccharide accelerates myelin phagocytosis during Wallerian degeneration in the injured mouse spinal cord.

Authors:  Nicolas Vallières; Jennifer L Berard; Samuel David; Steve Lacroix
Journal:  Glia       Date:  2006-01-01       Impact factor: 7.452

Review 3.  Macrophages and inflammatory mediators in tissue injury.

Authors:  D L Laskin; K J Pendino
Journal:  Annu Rev Pharmacol Toxicol       Date:  1995       Impact factor: 13.820

4.  Multimodal Enhancement of Remyelination by Exercise with a Pivotal Role for Oligodendroglial PGC1α.

Authors:  Samuel K Jensen; Nathan J Michaels; Slava Ilyntskyy; Michael B Keough; Olga Kovalchuk; V Wee Yong
Journal:  Cell Rep       Date:  2018-09-18       Impact factor: 9.423

5.  Fast gapped-read alignment with Bowtie 2.

Authors:  Ben Langmead; Steven L Salzberg
Journal:  Nat Methods       Date:  2012-03-04       Impact factor: 28.547

6.  Deficient Surveillance and Phagocytic Activity of Myeloid Cells Within Demyelinated Lesions in Aging Mice Visualized by Ex Vivo Live Multiphoton Imaging.

Authors:  Khalil S Rawji; Janson Kappen; Weiwen Tang; Wulin Teo; Jason R Plemel; Peter K Stys; V Wee Yong
Journal:  J Neurosci       Date:  2018-01-23       Impact factor: 6.167

7.  Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy.

Authors:  Jason R Plemel; Nathan J Michaels; Nina Weishaupt; Andrew V Caprariello; Michael B Keough; James A Rogers; Aran Yukseloglu; Jaehyun Lim; Vikas V Patel; Khalil S Rawji; Samuel K Jensen; Wulin Teo; Belinda Heyne; Shawn N Whitehead; Peter K Stys; V Wee Yong
Journal:  Glia       Date:  2017-10-25       Impact factor: 7.452

8.  Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology.

Authors:  Jean-Philippe Michaud; Maxime Hallé; Antoine Lampron; Peter Thériault; Paul Préfontaine; Mohammed Filali; Pascale Tribout-Jover; Anne-Marie Lanteigne; Rachel Jodoin; Christopher Cluff; Vincent Brichard; Rémi Palmantier; Anthony Pilorget; Daniel Larocque; Serge Rivest
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-15       Impact factor: 11.205

9.  Toll-like receptor 2-mediated alternative activation of microglia is protective after spinal cord injury.

Authors:  David P Stirling; Karen Cummins; Manoj Mishra; Wulin Teo; V Wee Yong; Peter Stys
Journal:  Brain       Date:  2013-12-24       Impact factor: 13.501

10.  Stimulation of phagocytosis in bone marrow-derived mouse macrophages by bacterial lipopolysaccharide: correlation with biochemical and functional parameters.

Authors:  P H Cooper; P Mayer; M Baggiolini
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

View more
  2 in total

1.  Complementing Neuroregeneration: Deciphering the Role of Neuro-Immune Interactions in CNS Repair.

Authors:  Sandra Jenkner; Ryan O'Hare Doig
Journal:  J Neurosci       Date:  2022-04-06       Impact factor: 6.709

Review 2.  Thinking outside the box: non-canonical targets in multiple sclerosis.

Authors:  Laura Bierhansl; Hans-Peter Hartung; Orhan Aktas; Tobias Ruck; Michael Roden; Sven G Meuth
Journal:  Nat Rev Drug Discov       Date:  2022-06-06       Impact factor: 112.288

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.